Cardioversion in Non-Valvular Atrial Fibrillation

Area of Science:

• Cardiology
• Cardiac Electrophysiology
• Internal Medicine

Background:

• Atrial fibrillation is a prevalent cardiac arrhythmia affecting 1.5-2% of the population.
• It significantly increases risks of stroke, heart failure, hospitalization, and mortality.
• Cardioversion is a key procedure to restore normal heart rhythm.

Purpose of the Study:

• To review the efficacy and safety of cardioversion for atrial fibrillation.
• To outline current guidelines for anticoagulation management during and after cardioversion.
• To assess the risks and benefits of electrical versus pharmacological cardioversion.

Main Methods:

• A selective PubMed search was conducted for articles published between 2004 and December 2014.
• Keywords used included "atrial fibrillation" and "cardioversion."
• The review synthesized findings on cardioversion techniques, outcomes, and anticoagulation protocols.

Main Results:

• Electrical cardioversion achieves sinus rhythm in over 85% of patients; pharmacological cardioversion in about 70% for recent-onset cases.
• Effective therapeutic anticoagulation (heparin, vitamin K antagonists, or new oral anticoagulants) is crucial.
• Pre-procedure echocardiography or prolonged anticoagulation is necessary for atrial fibrillation >48 hours; post-procedure anticoagulation is typically maintained for 4 weeks.

Conclusions:

• When performed according to guidelines, cardioversion has low rates (<1%) of major complications like thromboembolism and hemorrhage within 30 days.
• Adherence to therapeutic guidelines significantly minimizes serious risks associated with cardioversion.
• While rare, serious complications can still occur, emphasizing the importance of careful patient selection and management.